Published in Cancer Weekly, April 17th, 2006
Study 1: Investigators describe the efficacy of dendritic cell-based cancer immunotherapy targeting MUC-1 in a recent issue of Cancer Immunology Immunotherapy.
Researchers in Germany report, "Vaccination therapy using dendritic cells (DC) as antigen-presenting cells (APC) has shown significant promise in laboratory and animal studies as a potential treatment for malignant diseases. Pulsing of autologous DCs with tumor-associated antigens (TAA) is a method often used for antigen delivery and choice of suitable antigens plays an important role in designing an effective...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-04-17)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.